Mizuho raised the firm’s price target on Staar Surgical (STAA) to $18 from $17 and keeps a Neutral rating on the shares. The firm adjusted price targets in medical devices and diagnostics ahead of the Q2 reports.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STAA:
- Staar Surgical appoints Deborah Andrews as CFO
- Staar Surgical Appoints Deborah Andrews as CFO
- NeuroPace CFO Rebecca Kuhn to depart, Patrick Williams to succeed
- Staar Surgical Holds Annual Shareholders Meeting
- Cautious Optimism for Staar Surgical Amidst Uncertain Macroeconomic Recovery and Market Shifts